Phase 3 Mild Cognitive Impairment Clinical Trials
3 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–3 of 3 trials
Recruiting
Phase 3
GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
Type 2 DiabetesDementia, MildMild Cognitive Impairment
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School420 enrolled8 locationsNCT07083154
Recruiting
Phase 3
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
JYAMS PET Research & Development Limited316 enrolled2 locationsNCT07422857
Recruiting
Phase 3
Vitamin D and Cognition Trial
Mild Cognitive Impairment and vitamin D (25-hydroxyvitamin D) blood concentration between 50 nmol/L and 12.5 nmol/L.
Professor Nicola Lautenschlager110 enrolled1 locationACTRN12607000321448